Research Guide · TR-2

What is TR-2?

A dual-peptide tissue repair composite combining BPC-157 and TB-500 for complementary local angiogenesis and systemic cellular migration research.

Updated September 2026 Research Use Only 10 min read

What is TR-2

A two-component peptide composite delivering BPC-157 and TB-500 in one formulation for tissue-repair research models.

Composite Identity

TR-2 (Tissue Repair 2-component) is a research composite of BPC-157 + TB-500. Both components >99% HPLC verified.

Component Synergy

BPC-157 provides local angiogenic and cytoprotective effects via VEGF and nitric oxide pathways; TB-500 enables systemic cellular migration through G-actin sequestration. Together they address two rate-limiting steps in tissue repair: vascularisation and progenitor cell recruitment.

Research Use Only

For in-vitro laboratory research and animal model studies only. Not approved for human consumption or therapeutic application. Composite formulation is a vendor research convenience.

Component Mechanisms

Each peptide contributes a distinct molecular pathway.

BPC-157 — Pentadecapeptide Body Protection Compound

A 15-amino acid peptide derived from a protective sequence of human gastric juice. MW ~1,419 Da. Promotes angiogenesis through VEGF upregulation, nitric oxide synthase modulation, and FGF/EGF growth factor pathway potentiation. Established preclinical research in tendon-to-bone healing, GI ulcer recovery, and dopaminergic neuroprotection (Sikiric et al., 2012; Sikiric et al., 2014).

TB-500 — Thymosin Beta-4 Active Fragment

A 17-amino acid synthetic fragment containing the active actin-binding domain of the larger Thymosin Beta-4 (43-aa) protein. MW ~889 Da. Sequesters G-actin monomers, regulating cytoskeletal dynamics for cell migration to injury sites. Modulates inflammatory cytokine balance and supports endothelial cell migration (Crockford et al., 2010; Goldstein et al., 2012; Morris et al., 2015).

Combined Pathway Action

In repair models, TB-500 systemically mobilises and recruits progenitor cells to injury sites; BPC-157 establishes local angiogenic and growth-factor conditions that allow recruited cells to engraft and remodel tissue. The temporal complementarity — recruitment then vascularisation — is central to combined-protocol research interest.

TR-2 vs Single Peptides & Other Composites

How TR-2 compares to standalone protocols and related multi-component composites.

Protocol

Composition

Distinguishing Feature

TR-2

BPC-157 + TB-500 (20mg or 40mg)

Dual-pathway tissue repair without anti-inflammatory or copper components

BPC-157 alone

BPC-157 only

Local angiogenesis without TB-500’s systemic cellular recruitment

TB-500 alone

TB-500 only

Cellular migration without BPC-157’s local angiogenic/growth-factor priming

TR-3

TB-500 + BPC-157 + KPV (30mg)

Adds KPV for NF-κB anti-inflammatory pathway control

GLOW70

GHK-Cu + BPC-157 + TB-500 (70mg)

Adds GHK-Cu for collagen synthesis & copper signalling — dermal focus

Research Context: TR-2 is the simplest multi-pathway repair composite — no anti-inflammatory third component (KPV) and no copper signalling layer (GHK-Cu). For research models prioritising mechanistic clarity around the angiogenesis + migration axis without confounding pathways, TR-2 is the cleanest two-pathway option.

Key Research Applications

Primary research domains for the TR-2 composite.

Tendon & Ligament Repair Models

BPC-157 has the strongest preclinical literature for tendon and ligament repair, with TB-500 contributing accelerated cellular migration. Achilles transection, rotator cuff, and ACL reconstruction models are common research applications.

Muscle Injury Research

Acute muscle injury models (eccentric contraction, lacerations, contusions) benefit from combined cellular recruitment (TB-500) plus angiogenic priming (BPC-157), accelerating myofibre regeneration and reducing fibrotic scarring in rodent studies.

GI Ulcer & Mucosal Repair

BPC-157 has decades of preclinical research in gastric, duodenal, and colonic ulcer models. The TB-500 addition extends mechanistic exploration to inflammatory bowel disease models where cellular migration also plays a role.

Post-surgical Recovery Models

Combined tissue-repair protocols are studied in post-surgical incisional wound healing, anastomosis healing, and post-operative inflammation models, providing a research platform for accelerated recovery research.

Quick Reference Specifications

Key composite parameters.

P · 01

Designation

TR-2 (Tissue Repair 2-component composite)

P · 02

Components

BPC-157 + TB-500

P · 03

Component MWs

BPC-157 ~1,419 Da; TB-500 ~889 Da

P · 04

CAS Numbers

BPC-157: 137525-51-0; TB-500 (Tβ4 fragment): per supplier specification

P · 05

Purity

>99% HPLC per component

P · 06

Format

Lyophilised composite powder

P · 07

Mechanism Profile

Local angiogenesis (BPC-157) + systemic cellular migration (TB-500)

P · 08

Storage (Lyophilised)

2–8°C; protect from light

P · 09

Storage (Reconstituted)

2–8°C with bacteriostatic water; stable 2–4 weeks

Reconstitution & Storage

Handling guidance for the dual-peptide composite.

Reconstitution

Reconstitute with sterile bacteriostatic water (0.9% NaCl with 0.9% benzyl alcohol). Use sterile syringes; gentle dissolution by swirling — avoid shaking. Disposable pen format requires no reconstitution.

Storage Timeline

Reconstituted TR-2 maintains bioactivity for 2–4 weeks at 2–8°C. Both components are independently stable in the same diluent. Avoid freeze-thaw cycles.

Quality Control

Reconstituted solution should be clear and colourless. Cloudiness, particulates, or precipitate indicates degradation; discard. Visual inspection before each use is mandatory.

Handling Best Practices

Maintain refrigeration; minimise air exposure; use fresh sterile needles per withdrawal; document reconstitution date; discard solutions older than 4 weeks. Pen format should be stored upright after first use.

Component Evidence at a Glance

What the published literature supports for each ingredient.

BPC-157

Angiogenesis & tendon repair

Rodent tendon, muscle and ischaemia models, including FAK–paxillin and VEGFR2–Akt–eNOS signalling. Human data: a two-participant IV safety pilot (2025).^1–3

TB-500

Cell migration & wound closure

Full-length Tβ4 accelerated re-epithelialisation in rat wounds; the LKKTETQ actin-binding motif used in TB-500 reproduced key pro-angiogenic effects in vitro. No human data for the fragment.^4–6

Regulatory & Research Status

Component status in 2026.

APR 26

FDA Category 2 removal

BPC-157, TB-500 were among twelve peptides removed from the US FDA’s Category 2 compounding list. This is not an approval.

JUL 26

Advisory committee votes

The FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend BPC-157 and TB-500 individually for the 503A bulks list. The votes are non-binding and do not cover combination products.

SPORT

WADA 2026

BPC-157 (S0) and TB-500 (S2) are prohibited at all times.

Evidence Quality & Limitations

No peer-reviewed study has tested TR-2 as a combination. The rationale rests on each component’s individual evidence and complementary mechanisms, so “synergy” is a hypothesis to test rather than an established finding. Component ratios reflect the product formulation rather than published dose-response work, and the stability and compatibility of the peptides stored together in one solution have not been characterised in the literature. Nearly all component data are preclinical.

References

Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774–80. PubMed
Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323–33. PubMed
Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20–4. PubMed
Malinda KM, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364–8. PubMed
Philp D, et al. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17:2103–5. PubMed
Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. J Chromatogr A. 2012;1265:57–69. PubMed

⚠ Research Use Only. The compounds discussed in this guide are intended strictly for in-vitro laboratory research. Not for human consumption, therapeutic use, or veterinary application. Researchers must comply with all applicable local regulations.